01.002 RWE TNT May 2022 C 18-05-2022

AstraZeneca and Pfizer vaccines effective against Delta variant

  • The study found that the effectiveness of BNT162b2 [Pfizer-BioNTech] and ChAd0x1 [Oxford-AstraZeneca] against any infections (new PCR positives) and infections with symptoms or high viral burden is reduced with the Delta variant
  • Two doses of either vaccine still provided at least the same level of protection as having had COVID-19 before through natural infection; people who had been vaccinated after already being infected with COVID-19 had even more protection than vaccinated individuals who had not had COVID-19 before
  • However, Delta infections after two vaccine doses had similar peak levels of virus to those in unvaccinated people; with the Alpha variant, peak virus levels in those infected post-vaccination were much lower
Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at